Informing interventions to improve uptake of adjuvant endocrine therapy in women with breast cancer: a theoretical-based examination of modifiable influences on non-adherence

[1]  R. Olofsson Bagge,et al.  Women’s coping strategies during the first three months of adjuvant endocrine therapy for breast cancer , 2019, Nursing open.

[2]  Lyndsay D. Hughes,et al.  Development of a self-management intervention to improve tamoxifen adherence in breast cancer survivors using an Intervention Mapping framework , 2019, Supportive Care in Cancer.

[3]  Lyndsay D. Hughes,et al.  Nonadherence to tamoxifen in breast cancer survivors: A 12 month longitudinal analysis. , 2019, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[4]  J. Borrás,et al.  Influence of adherence to adjuvant endocrine therapy on disease-free and overall survival: a population-based study in Catalonia, Spain , 2019, Breast Cancer Research and Treatment.

[5]  R. Horne,et al.  Supporting Adherence to Medicines for Long-Term Conditions: A Perceptions and Practicalities Approach Based on an Extended Common-Sense Model , 2019, European Psychologist.

[6]  A. Salner,et al.  Interventions to promote adherence to endocrine therapy among breast cancer survivors: A meta‐analysis , 2018, Psycho-oncology.

[7]  A. Stanton,et al.  Correspondence Between Objective and Self-reported Endocrine Therapy Adherence Among Women With Breast Cancer. , 2019, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

[8]  Tisha M Felder,et al.  A systematic review of interventions to improve adherence to endocrine therapy , 2018, Breast Cancer Research and Treatment.

[9]  C. Gotay,et al.  Understanding adjuvant endocrine therapy persistence in breast Cancer survivors , 2018, BMC cancer.

[10]  V. Harvey,et al.  Predicting nonadherence to adjuvant endocrine therapy in women with early stage breast cancer , 2018, Psycho-oncology.

[11]  Melissa Matz,et al.  Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries , 2018, The Lancet.

[12]  C. Gotay,et al.  Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review , 2018, Breast Cancer Research and Treatment.

[13]  J. Wisnivesky,et al.  Patient-provider communication and hormonal therapy side effects in breast cancer survivors , 2017, Women & health.

[14]  N. Barnett,et al.  Using Theory to Explore the Determinants of Medication Adherence; Moving Away from a One-Size-Fits-All Approach , 2017, Pharmacy.

[15]  M. Browall,et al.  Assessing patient outcomes and cost‐effectiveness of nurse‐led follow‐up for women with breast cancer – have relevant and sensitive evaluation measures been used? , 2017, Journal of clinical nursing.

[16]  J. Cuzick,et al.  Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I) , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  K. Bennett,et al.  Developing and validating a theoretical measure of modifiable influences on hormonal therapy medication taking behaviour in women with breast cancer , 2017, Psychology & health.

[18]  K. Bennett,et al.  Can demographic, clinical and treatment-related factors available at hormonal therapy initiation predict non-persistence in women with stage I–III breast cancer? , 2017, Cancer Causes & Control.

[19]  Jinbo Chen,et al.  Perceived barriers to treatment predict adherence to aromatase inhibitors among breast cancer survivors , 2017, Cancer.

[20]  E. Smets,et al.  Use of implicit persuasion in decision making about adjuvant cancer treatment: A potential barrier to shared decision making. , 2016, European journal of cancer.

[21]  V. Sheppard,et al.  Behavioral Interventions to Enhance Adherence to Hormone Therapy in Breast Cancer Survivors: A Systematic Literature Review. , 2016, Clinical breast cancer.

[22]  Aaron N. Winn,et al.  The association between trajectories of endocrine therapy adherence and mortality among women with breast cancer , 2016, Pharmacoepidemiology and drug safety.

[23]  Jason D. Wright,et al.  Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the Breast Cancer Quality of Care Study (BQUAL) , 2016, Breast Cancer Research and Treatment.

[24]  R. Horne,et al.  Applying a perceptions and practicalities approach to understanding nonadherence to antiepileptic drugs , 2015, Epilepsia.

[25]  K. Bennett,et al.  Women’s experiences of hormonal therapy for breast cancer: exploring influences on medication-taking behaviour , 2015, Supportive Care in Cancer.

[26]  K. Bennett,et al.  A nested case–control study of adjuvant hormonal therapy persistence and compliance, and early breast cancer recurrence in women with stage I–III breast cancer , 2013, British Journal of Cancer.

[27]  F. Song,et al.  A meta-analysis of cognitive-based behaviour change techniques as interventions to improve medication adherence , 2013, BMJ Open.

[28]  C. Abraham,et al.  The Behavior Change Technique Taxonomy (v1) of 93 Hierarchically Clustered Techniques: Building an International Consensus for the Reporting of Behavior Change Interventions , 2013, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

[29]  Sally W. Vernon,et al.  Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review , 2012, Breast Cancer Research and Treatment.

[30]  Jeffrey K Aronson,et al.  A new taxonomy for describing and defining adherence to medications. , 2012, British journal of clinical pharmacology.

[31]  S. Michie,et al.  Validation of the theoretical domains framework for use in behaviour change and implementation research , 2012, Implementation Science.

[32]  Early Breast Cancer Trialists' Collaborative Group.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.

[33]  M. Tsolaki,et al.  A Multiple Indicators Multiple Causes (MIMIC) model of Behavioural and Psychological Symptoms in Dementia (BPSD) , 2011, Neurobiology of Aging.

[34]  S. Iacobelli,et al.  Discussion about switch strategy in the adjuvant hormonal therapy of breast cancer: psychological aspects of physician-patient communication. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  Mahendra Patel,et al.  Medicines adherence: Involving patients in decisions about prescribed medicines and supporting adherence , 2009 .

[36]  L. Fallowfield,et al.  Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy , 2007, Breast Cancer Research and Treatment.

[37]  Ann E. Kurth,et al.  Self-Report Measures of Antiretroviral Therapy Adherence: A Review with Recommendations for HIV Research and Clinical Management , 2006, AIDS and Behavior.

[38]  S. Erickson,et al.  The Concordance of Self-Report With Other Measures of Medication Adherence: A Summary of the Literature , 2004, Medical care.

[39]  J. Weinman,et al.  Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. , 1999, Journal of psychosomatic research.

[40]  C. Carver.  You want to measure coping but your protocol’ too long: Consider the brief cope , 1997, International journal of behavioral medicine.

[41]  D. Watson,et al.  Constructing validity: Basic issues in objective scale development , 1995 .

[42]  C. Fornell,et al.  Evaluating Structural Equation Models with Unobservable Variables and Measurement Error , 1981 .

[43]  C. Fornell,et al.  Evaluating structural equation models with unobservable variables and measurement error. , 1981 .

[44]  A. Cunliffe.  A SUMMARY OF THE LITERATURE , 1924 .